The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer

Molecular Biology Reports

Volumn 41, Issue 4, 2014, Pages 2275-2279

  Cavia Saiz, M ^a   Muniz Rodriguez P ^b   Llorente Ayala, B ^a   Garcia Gonzalez M ^a   Coma Del Corral, M J ^a   Garcia Giron C ^a  

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^b UNIVERSITY OF BURGOS   (Spain)

Author keywords

Biomarker; Colorectal cancer; Indoleamine 2,3 dioxygenase; l Kynurenine

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; INDOLEAMINE 2,3 DIOXYGENASE; IRINOTECAN; KYNURENINE; OXALIPLATIN; TUMOR MARKER;

AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; BLOOD; CANCER GRADING; CASE CONTROL STUDY; COLORECTAL NEOPLASMS; ENZYME ACTIVATION; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; ENZYME ACTIVATION; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84897563217     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-014-3080-2     Document Type: Article

References (29)

1. Karsa LV, Lignini TA, Patnick J, Lambert R, Sauvaget C (2010) The dimensions of the CRC problem. Best Pract Res Clin Gastroenterol 24:381-396
2. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O (2003) Clinical utility of biochemical markers in colorectal cancer: European group on tumor markers (EGTM) guidelines. Eur J Cancer 39:718-727 (Pubitemid 36315986)
3. Carpelan-Holmstrom M, Louhimo J, Stenman UA, Alfthan H, Jarvinen H, Haglund C (2004) Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology 66:296-302 (Pubitemid 38822799)
4. Basbug M, Arikanoglu Z, Bulbuller N, Cetinkaya Z, Aygen E, Akbulut S, Satici O (2011) Prognostic value of preoperative CEA and CA 19-9 levels in patients with colorectal cancer. Hepatogastroenterology 58:400-405
5. Tjalsma H (2010) Identification of biomarkers for colorectal cancer through proteomics-based approaches. Expert Rev Proteomics 7:879-895
6. Babel I, Barderas R, Díaz-Uriarte R, Martínez-Torrecuadrada JL, Sánchez-Carbayo M, Casal JI (2009) Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol Cell Proteomics 8:2382-2395
7. Silk AW, Schoen RE, Potter DM, Finn OJ (2009) Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Mol Immunol 47:52-56
8. Ran Y, Hu H, Zhou Z, Yu L, Sun L, Pan J, Liu J, Yang Z (2008) Profiling tumor-associated autoantibodies for the detection of colon cancer. Clin Cancer Res 14:2696-2700
9. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O (2007) Tumor markers in colorectal cancer: European group on tumor markers (EGTM) guidelines for clinical use. Eur J Cancer 43:1348-1360 (Pubitemid 46874070)
10. Ninomiya S, Hara T, Tsurumi H, Hoshi M, Kanemura N, Goto N, Kasahara S, Shimizu M, Ito H, Saito K, Hirose Y, Yamada T, Takahashi T, Seishima M, Takami T, Moriwaki H (2011) Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 90:409-416
11. Nonaka H, Saga Y, Fujiwara H, Akimoto H, Yamada A, Kagawa S, Takei Y, Machida S, Takikawa O, Suzuki M (2011) Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killer cell function and angiogenesis promotion. Int J Oncol 38:113-120
12. Inaba T, Ino K, Kajiyama H, Shibata K, Yamamoto E, Kondo S, Umezu T, Nawa A, Takikawa O, Kikkawa F (2010) Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy. Gynecol Oncol 117:423-428
13. Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, Nawa A, Nagasaka T, Takikawa O, Kikkawa F (2008) Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 14:2310-2317 (Pubitemid 351551062)
14. Polak ME, Borthwick NJ, Gabriel FG, Johnson P, Higgins B, Hurren J, McCormick D, Jager MJ, Cree IA (2007) Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 960:1879-1887 (Pubitemid 46912012)
15. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Göbel G, Margreiter R, Königsrainer A, Fuchs D, Amberger A (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12:1144-1151 (Pubitemid 43342502)
16. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269-1274 (Pubitemid 37279849)
17. Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117:1147-1154 (Pubitemid 46718399)
18. Gao YF, Peng RQ, Li J, Ding Y, Zhang X, Wu XJ, Pan ZZ, Wan DS, Zeng YX, Zhang XS (2009) The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer. J Transl Med 7:71
19. Cavia-Saiz M, Muñiz P, De Santiago R, Herreros-Villanueva M, Garcia-Giron C, Lopéz AS, Coma-del Corral MJ (2012) Changes in the levels of thioredoxin and indoleamine-2-3 dioxygenase activity in plasma of patients with colorectal cancer treated with chemotherapy. Biochem Cell Biol 90:173-178
20. Alegre E, López AS, González A (2005) Tryptophan metabolites interfere with the Ehrlich reaction used for the measurement of kynurenine. Anal Biochem 339:188-189 (Pubitemid 40342697)
21. Singer K, Gottfried E, Kreutz M, Mackensen A (2011) Suppression of T-cell responses by tumor metabolites. Cancer Immunol Immunother 60:425-431
22. Laimer K, Troester B, Kloss F, Schafer G, Obrist P, Perathoner A, Laimer J, Brandacher G, Rasse M, Margreiter R, Amberger A (2011) Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas. Oral Oncol 47:352-357
23. Pan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J, Huang W, Li JJ, Song HF, Xia JC (2008) Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 134:1247-1253
24. Johnson BA, Baban B, Mellor AL (2009) Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy 1:645-661
25. Ciorba MA (2013) Indoleamine 2,3 dioxygenase in intestinal disease. Curr Opin Gastroenterol 29:146-152
26. Mead R, Duku M, Bhandari P, Cree IA (2011) Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer 105:239-245
27. Zhu CB, Wang CX, Zhang X, Zhang J, Li W (2011) Serum sHLA-G levels: A useful indicator in distinguishing colorectal cancer from benign colorectal diseases. Int J Cancer 128:617-622
28. Yoshikawa T, Hara T, Tsurumi H, Goto N, Hoshi M, Kitagawa J, Kanemura N, Kasahara S, Ito H, Takemura M, Saito K, Seishima M, Takami T, Moriwaki H (2010) Serum concentration of l-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol 84:304-309
29. Seval Kul (2010) The use of survival analysis for clinical pathways. Int J Care Pathw 14:23-26